843
Views
3
CrossRef citations to date
0
Altmetric
Commentary

Time to look for CD30 expression in diffuse large B-cell lymphomas, along the way to immunotherapy

Pages 2341-2342 | Published online: 15 May 2013

References

  • Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leuk Lymphoma 2013;54:2405–2411.
  • Durkop H, Latza U, Hummel M. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421–427.
  • Falini B, Pileri S, Pizzolo G. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1–14.
  • Podack ER, Strbo N, Sotosec V. CD30-governor of memory T cells?Ann NY Acad Sci 2002;975:101–113.
  • Deutsch YE, Tadmor T, Podack ER. CD30: an important new target in hematologic malignancies. Leuk Lymphoma 2011;52:1641–1654.
  • Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011;23:587–593.
  • Fromm JR, McEarchern JA, Kennedy D. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentiximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk 2012;12:280–283.
  • Sotlar K, Cerny-Reiterer C, Petat-Dutter K. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011;24:585–595.
  • Gardner LJ, Polski JM, Evans HL. CD30 expression in follicular lymphoma. Arch Pathol Lab Med 2001;125:1036–1041.
  • Latza U, Foss H-D, Dürkop H. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol 1995;146:463–471.
  • Dürkop H, Foss H-D, Eitelbach F. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol 2000;190:613–618.
  • Hu S, Xu-Monette ZY, Balasubramanyam A. CD30 expression defines a novel subset of diffuse large B cell ymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013 Jan 23. [Epub ahead of print]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.